ACM
ATRA icon

ACT Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

ACT Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3K Sell
36
-332
-90% -$37.3K ﹤0.01% 71
2022
Q2 		$72K Hold
368
– – 0.1% 56
2022
Q1 		$85K Hold
368
– – 0.09% 68
2021
Q4 		$145K Sell
368
-4,308
-92% -$1.81M 0.1% 75
2021
Q3 		$2.09M Hold
4,676
– – 1.08% 17
2021
Q2 		$1.82M Buy
+4,676
New +$1.67M 0.93% 27

Other funds holding ATRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACT Capital Management's ATRA Position: Q3 2022 in Review

ACT Capital Management reduced its Atara Biotherapeutics (ATRA) stake by 90% in Q3 2022, selling an estimated $37.3K and leaving 36 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #71.

ACT Capital Management first reported a position in ATRA in Q2 2021 and has held it in 6 quarters since. The position peaked at $2.09M in Q3 2021. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

  • ACT Capital Management held 36 shares of Atara Biotherapeutics worth $3K as of Q3 2022.
  • ACT Capital Management sold 332 Atara Biotherapeutics shares in Q3 2022, an estimated $37.3K.
  • Atara Biotherapeutics made up ﹤0.01% of ACT Capital Management's portfolio in Q3 2022, its #71 holding.
  • ACT Capital Management first reported a position in Atara Biotherapeutics in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Atara Biotherapeutics position peaked at $2.09M in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.